Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2754242 | 0.75 | RAB9A (0.70) | BCHECYP2D6LMNAHTTKDM4E | |
| SCHEMBL877544 | 0.74 | KMT2A (0.57) | LMNAKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL30492135 | 0.74 | HTR6 (0.51) | BCHECYP2D6LMNAHTTKDM4E | |
| SCHEMBL7094297 | 0.74 | BCHE (0.42) | BCHECYP2D6LMNAHTTKDM4E | |
| SCHEMBL9027196 | 0.73 | CYP2D6 (0.49) | BCHECYP2D6LMNAHTTKDM4E | |
| SCHEMBL3996399 | 0.72 | BCHE (0.55) | BCHECYP2D6LMNAHTTKDM4E | |
| SCHEMBL8563554 | 0.71 | BCHE (0.57) | BCHECYP2D6LMNAHTTKDM4E | |
| SCHEMBL16085665 | 0.71 | GSK3A (0.54) | CYP2D6MEN1KMT2APOLBTSHR | |
| SCHEMBL8872774 | 0.69 | BCHE (0.73) | BCHECYP2D6LMNAHTTKDM4E | |
| SCHEMBL24939934 | 0.69 | CYP2D6 (0.56) | BCHECYP2D6LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206186-B2 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140005176-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-1997495-B1 | 2-phenoxy- and 2-phenylsulfanyl-benzenesulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS INC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-7674797-B2 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20090286771-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | LI YINGFU | 2009-11-19 | — | — | US | disclosed |
| EP-1608374-B9 | 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS INC (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-1997495-A1 | 2-phenoxy- and 2-phenylsulfanyl-benzenesulfonamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | Actimis Pharmaceuticals, Inc., (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1608374-B1 | 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS INC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20070155725-A1 | 2-Phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| EP-1608374-A1 | 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS | Actimis Pharmaceuticals, Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004084898-A1 | 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS, INC. (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286771-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | CCR3, CCR2, CCR1 | BCHE 327/4885CYP2D6 1499/4885LMNA 4432/4885 |
| US-20140005176-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | CCR3, CCR2, CCR1 | BCHE 327/4885CYP2D6 1499/4885LMNA 4432/4885 |
| US-20070155725-A1 | 2-Phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | CCR3, CCR1, CCR2 | BCHE 753/4885CYP2D6 789/4885LMNA 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.